Steven Potkin, MD

A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Patients With Acute Exacerbation of Schizophrenia

Background: ALKS 3831, under development for the treatment of schizophrenia, is composed of olanzapine and samidorphan. In a prior study, samidorphan mitigated olanzapine-associated weigh...

Ying Jiang , PhD;

Bernard Silverman , MD;

Lauren DiPetrillo , PhD;

Steven Potkin , MD;

Adam Simmons , MPH;

David McDonnell , MD;

03/01/2019

Neurobiology of Treatment-Resistant Schizophrenia

Treatment-resistant schizophrenia (TRS) occurs in up to 30% of patients with schizophrenia and is defined as the persistence of positive symptoms despite ≥2 trials of antipsychotic (AP) m...

John Kane , MD;

Steven Potkin , MD;

Jean-Pierre Lindenmayer , MD;

Ofer Agid , MD;

Christoph U. Correll , MD;

Stephen Marder , MD;

Oliver Howes , MD;

03/01/2019